Post-earnings recap
Reported
Mon, May 12, 2025
EPS actual
$2.75
EPS est.
$-0.06
EPS surprise
+4683.33%
1-day move
+7.21%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a significant earnings surprise, with EPS far exceeding expectations. The stock rose by 7.21% following the announcement, reflecting investor confidence in the company's performance. However, the lack of revenue data and guidance leaves some uncertainty about future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.75 | N/A | +4683.33% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They emphasized the importance of long-term growth.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and delivering value.